Conduct studies to monitor the integrity and reliability of in vivo tumor systems and rodents used in the cancer drug development program of the development Therapeutics Program (DTP). To be accomplished through collection of kinetic data and evaluation of drug testing using standard and experimental agents. Develop in vivo protocols for candidate tumor models from the human tumor cell line diseaseoriented screen so as to provide the necessary tools for the followup of active materials identified as having potential for development for possible clinical trial. This protocol development will include the testing of standard and experimental drugs to evaluate their effectiveness against new in vivo models. In addition, host animals for these tumor systems must be monitored and subjected to vigorous quality control.
| Plowman, J; Dykes, D J; Narayanan, V L et al. (1995) Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice. Cancer Res 55:862-7 |
| Malkinson, A M; Siegel, D; Forrest, G L et al. (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res 52:4752-7 |
